UNSPSC 51241138: Cyclopentolate

This classification denotes a mydriatic agent and antimuscarinic agent with the molecular formula C17H25NO3, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier I76F4SHP7J, chemically known as benzeneacetic acid, alpha-(1-hydroxycyclopentyl)-, 2-(dimethylamino)ethyl ester but more generally known as cyclopentolate, which bears U.S. NIH Compound Identifier 2905. European Medicines Agency schedules Cyclopentolate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06858MIG.

UNSPSC 51241138 Cyclopentolate is a Commodity code covering pharmaceutical active ingredients and finished pharmaceuticals. State and local governments procure cyclopentolate and related generic pharmaceuticals through cooperative purchasing vehicles administered by multistate alliances, where the purchasing scope encompasses establishment of master contracts with manufacturers for supply through authorized wholesalers to state agencies, counties, municipalities, school districts, and other public health and institutional facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary recent issuing body under this code, leveraging cooperative procurement to aggregate demand across participating states including Oregon and to standardize supplier relationships, pricing, compliance certifications, and product specifications across jurisdictions. Manufacturers responding to opportunities under this code must maintain cGMP certification and DSCSA compliance, sustain contractual relationships with authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co.), and offer flexible pricing structures including fixed pricing, net pricing at various terms, or WAC-minus formats.

MMCAP's most recent solicitation, posted January 20, 2026, is the Representative opportunity under this code: an RFP for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026. Award criteria emphasize price competitiveness (75 percent weight), with secondary evaluation of fixed pricing structure, administrative compliance, EDI capability, and willingness to accept MMCAP's 3 percent administrative fee. Products must be available in the marketplace by May 15, 2026, with resulting agreements effective July 1, 2026 for two years with optional extensions, or amended through June 30, 2028 for incumbent responders. The RFP does not disclose a specific budget range or total contract value. Vendors must maintain $5,000,000 commercial general liability insurance, $2,000,000 network security and privacy liability, and $2,000,000 professional liability coverage, and products must meet FDA requirements with minimum one-year expiration dates and six-month shelf life from manufacture.